- Home
- CLPR vs NRXP Comparison
CLPR vs NRXP Comparison
Compare CLPR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | NRXP |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 54.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPR | NRXP |
|---|---|---|
| Price | $3.07 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 59.0K | ★ 497.3K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 11.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $3.04 | $1.58 |
| 52 Week High | $4.61 | $3.84 |
Technical Indicators
Market Signals| Indicator | CLPR | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 33.07 | 49.93 |
| Support Level | $3.04 | $1.65 |
| Resistance Level | $3.96 | $1.99 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 6.67 | 63.49 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.